6-Methyl-8-(methylthio)-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine

Catalog No. :
ACOLQE935
CAS No. :
1094070-48-0
Molecular Formula :
C17H25N5OSSi
Molecular Weight :
375.57

IUPAC Name:6-methyl-8-(methylthio)-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine

6-Methyl-8-(methylthio)-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$524.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-Methyl-8-(methylthio)-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine
IUPAC Name6-methyl-8-(methylthio)-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine
Molecular FormulaC17H25N5OSSi
Molecular Weight375.57
SMILESC[Si](CCOCN1N=CC(C2=CN=C3C(SC)=NC(C)=CN32)=C1)(C)C
InChI KeyVIGZPODBNYIHDD-UHFFFAOYSA-N
Synonymtrimethyl-[2-[[4-(6-methyl-8-methylsulfanylimidazo[1,2-a]pyrazin-3-yl)pyrazol-1-yl]methoxy]ethyl]silane;6-Methyl-8-(methylthio)-3-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-yl]imidazo[1,2-a]pyrazine
CAS No.1094070-48-0

Synthetic Route by SureRoute

1. ACOLQE935 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHQAN673 route compound structure diagram
    ACHQAN673894807-98-8 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOLQE935 route product structure diagram
    ACOLQE9351094070-48-0 In Stock
Inquiry

2. ACOLQE935 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHQAN673 route compound structure diagram
    ACHQAN673894807-98-8 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOLQE935 route product structure diagram
    ACOLQE9351094070-48-0 In Stock
Inquiry

Comments (0)